Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 2.50B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -157.24M |
| Shares Out | 105.87M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 756,029 |
| Open | 23.72 |
| Previous Close | 23.71 |
| Day's Range | 23.48 - 24.27 |
| 52-Week Range | 10.60 - 35.50 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 35.89 (+52.14%) |
| Earnings Date | Nov 6, 2025 |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tria... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $35.89, which is an increase of 52.14% from the latest price.
News
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo. , Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic...
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran...
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies an...
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the f...
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
– Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – – MESA open-label extension trial of sevasemte...
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th Internation...
Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announce...
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $EWTX--EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial and FDA Type C meeting provide clear path...
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
BOULDER, Colo. , June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annua...
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
BOULDER, Colo. , May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC C...
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from...
Why Edgewise Therapeutics Stock Popped This Week
On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compi...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook ...
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopa...
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering o...
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantia...
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team wil...
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an i...
Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targetin...
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners G...
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year ...